$982.29
14.31[1.48%]
At close: May 17
$982.29
0[0.00%]
After Hours: 4:00PM EDT
Regeneron Pharmaceuticals
(NASDAQ:REGN)Regeneron Pharmaceuticals Stock (NASDAQ:REGN), Analyst Ratings, Price Targets, Predictions
Regeneron Pharmaceuticals Inc has a consensus price target of $906.63, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Evercore ISI Group, Cantor Fitzgerald, and TD Cowen on May 14, 2024, May 3, 2024, and April 24, 2024. With an average price target of $1035 between Evercore ISI Group, Cantor Fitzgerald, and TD Cowen, there's an implied 5.37% upside for Regeneron Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
Cantor Fitzgerald
TD Cowen
UBS
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Regeneron Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | 17.07% | Evercore ISI Group | Cory Kasimov | → $1150 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | -5.83% | Cantor Fitzgerald | Olivia Brayer | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/24/2024 | Buy Now | 4.86% | TD Cowen | Tyler Van Buren | $1020 → $1030 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 11.88% | UBS | Colin Bristow | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | -5.83% | Cantor Fitzgerald | Olivia Brayer | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | Buy Now | -5.83% | Cantor Fitzgerald | Louise Chen | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | Buy Now | -26.7% | B of A Securities | Geoff Meacham | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | Buy Now | 21.04% | RBC Capital | Brian Abrahams | → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 15.55% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 15.55% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 13.51% | Morgan Stanley | Matthew Harrison | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 14.53% | Bernstein | William Pickering | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 14.53% | Bernstein | Aaron Gal | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 20.53% | RBC Capital | Brian Abrahams | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | -5.83% | Cantor Fitzgerald | Olivia Brayer | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 13% | RBC Capital | Brian Abrahams | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 10.15% | BMO Capital | Evan David Seigerman | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 9.54% | RBC Capital | Brian Abrahams | → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | 3.84% | Barclays | Carter Gould | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | Buy Now | 9.54% | RBC Capital | Brian Abrahams | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | Buy Now | -13.47% | Cantor Fitzgerald | Olivia Brayer | → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | Buy Now | 6.38% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | Buy Now | 1.8% | TD Cowen | Tyler Van Buren | $900 → $1000 | Maintains | Outperform | Get Alert |
| 11/29/2023 | Buy Now | 6.38% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | -4.61% | Jefferies | Akash Tewari | $935 → $937 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 6.38% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | -18.56% | Deutsche Bank | James Shin | → $800 | Initiates | → Hold | Get Alert |
| 11/03/2023 | Buy Now | -8.89% | Piper Sandler | Christopher Raymond | $885 → $895 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -14.79% | RBC Capital | Brian Abrahams | $847 → $837 | Maintains | Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | -6.95% | Morgan Stanley | Matthew Harrison | $915 → $914 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN)?
The latest price target for Regeneron Pharmaceuticals (NASDAQ: REGN) was reported by Evercore ISI Group on May 14, 2024. The analyst firm set a price target for $1150.00 expecting REGN to rise to within 12 months (a possible 17.07% upside). 63 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ: REGN) was provided by Evercore ISI Group, and Regeneron Pharmaceuticals initiated their outperform rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on June 28, 2023 when Canaccord Genuity changed their price target from $953 to $720 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a initiated with a price target of $0.00 to $1150.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $982.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.